1 / 35

A R D S

A R D S. Jhansi Nalamati MD FCCP Asst. Prof. Of Medicine, AECOM BRONX NY. Definition. Acute Respiratory Distress Syndrome First described in 1967 in Lancet as Adult Respiratory Distress Syndrome by Asbaugh et.al.

morwen
Download Presentation

A R D S

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A R D S Jhansi Nalamati MD FCCP Asst. Prof. Of Medicine, AECOM BRONX NY

  2. Definition • Acute Respiratory Distress Syndrome • First described in 1967 in Lancet as Adult Respiratory Distress Syndrome by Asbaugh et.al. • 12 pts. had developed acute respiratory distress, cyanosis , diffuse pulmonary infiltrates decreased lung compliance and was refractory to Oxygen therapy • Also called as “wet lung”, “shock lung” and “Da Nang lung”

  3. Incidence • Crude estimates of 78.9/100,000 person years • In patient mortality 38.5% • 190,600 cases/year in the US with 74,500 deaths and 3.6 million hospital days

  4. ARDS and ALI (Acute Lung Injury) in 1992 • Defined by American European Consensus • “Acute Lung Injury” is an umbrella term for “ Hypoxemia Respiratory Failure” , a severe version of which is “ARDS”. • Bilateral Infiltrates • PCWP< 18mm Hg • PaO2/FiO2< 300 = ALI • PaO2/FiO2<200 =ARDS

  5. ALI/ARDS ( Addl. Features) • Bilateral widespread infiltrates on CXR • Airway collapse ( low lung Volumes) • Surfactant deficiency • Reduced lung compliance

  6. Etiology • Direct insult to the lungs- bacterial, viral, fungal agents, lung contusion, Fat embolism • Systemic medical and surgical conditions- trauma, shock, sepsis, burns, pancreatitis • Noxious agents- exposure to smoke , aspiration

  7. PATHOPHYSIOLOGY • Altered Pulmonary Capillary Permeability secondary to endothelial injury • Altered alveolar diffusion capacity • Increased intrapulmonary shunt • Degree of epithelial injury can predict outcome

  8. Patho-physiology(contd.) • Loss of epithelial integrity and injury to type II alveolar cells can disrupt fluid transport thereby leading to impairing the removal of fluid from alveolar space • Injury to type II pneumocytes can reduce the production of surfactant which leads to worsening atelectasis and gas exchange

  9. Histo-pathological phases • 1) Exudative Phase: 1-3 days- diffuse alveolar damage ( DAD) with majority of type I pneumocyte necrosis, diffuse microvascular injury and influx of inflammatory cells and proteinaceous fluid into the interstitium

  10. Fibroproliferative phase • Day 3-7- repair manifested by type I pneumocyte hyperplasia and proliferation of fibroblasts

  11. Treatment of ARDS • Corner stone of treatment is to keep PaO2 >60mm Hg, without causing injury to lung with excessive O2 or excessive TV ( FiO2 < 60% and TV of 6ml/kg) • Plateau pressure should not exceed 30mmHg and minimal TV should be at least 4ml/kg ( irrespective of MAP or plateau pressure) • “Avoid Volutrauma and Barotrauma”

  12. ATS recommendations • Minimize O2 toxicity • Recruit alveoli • Minimize high airway pressures • Prevent atelectasis • Use sedation and paralysis judiciously

  13. Tx of ARDS/ALI • “SUPPORTIVE CARE” • “SUPPORTIVE CARE” • “SUPPORTIVE CARE”

  14. Low Tidal Volume Ventilation with or without High PEEP • Minimizes the amount of phasic stretch of lung units in inspiration to prevent VILI( Ventilator Induced Lung Injury) • Proven to be effective in an NIH coordinated multi center trial( NEJM ), patients ventilated with TV of 6ml/kg had a 22% reduction in mortality compared to patients ventilated with TV of 10-12ml/kg

  15. Open Lung approach • Attempts to optimize lung mechanics and minimize phasic damage by strategically placing PEEP above Pflex. • Quasi- Static Volume Pressure curve- the lungs are said to be most compliant between the lower inflection point and the upper inflection point, beyond which over distension occurs

  16. PCV( Pressure Controlled ventilation) • Better gas distribution than volume control ventilation by avoiding over distension of low complaint units • Plateau pressure not to exceed 30mm of Hg • Reverse I:E Ratio

  17. APRV ( Airway pressure release ventilation) • Sets pressure high and pressure low and time high and time low • Patient can spontaneously breathe within these limits, minimizing sedation requirements • Unclear what is the PEEP ( ? Pressure high, ? Pressure low, ? Mean)

  18. HFV ( High frequency ventilation) • Reduces barotrauma and improves VQ mismatch • Potential complications- inspication of mucus, airway damage due to high gas velocities and over distension causing alveolar injury and worsening ALI

  19. Tx ( contd.) • Prone Positioning • Permissive Hypercapnia ( potential complications include pulmonary vasoconstriction, pulmonary HTN, proarrhythmic effects, cerebral vasodilatation, increasing ICP) • Prophylactic Bil. chest tubes

  20. Inhaled Nitric Oxide • Improves oxygenation and decreases Pulmonary Vascular Resistance • Dose varies from 1.25 to 40ppm • NO clear benefit in limited randomized controlled trials • Needs to be given for days to weeks • Sensitization can occur • Can cause renal dysfunction, immunosuppression, potentially mutagenic , can cause methhemoglobinemia and NO2 concentration

  21. Steroids in ARDS • Controversial • Cytokines decline over the first week in survivors of ARDS, but persist in non survivors

  22. Steroid regimen( Prednisone) • 2mg/kg day 1-14 • 1mgkg day 15-21 • 0.5mg/kg day 22-28 • 0.25mg/kg day 29-30 • 0.125mg/kg day 31-32 • Not to be started before 7days of ALI or admission or beyond 28days of ALI or admission

  23. Novel therapies for ARDS • Albuterol • Salmetrol • Surfactant • Pentoxyfylline • Cyclooxygenase inhibitors • Antioxidants • TNF antibodies infusion • PAF inhibitors and receptor antagonists • Antiproteases

  24. Cause of death • Underlying cause • Secondary complications- sepsis from ventilator associated pneumonia, GI bleed, multi organ failure

  25. Management of secondary effects • Judicious use of sedation and neuromuscular blockade • Hemodynamic management • Nutritional support • Glucose control • Nosocomial pneumonia prevention and Tx • GI and DVT prophylaxis

  26. Nosocomial Pneumonia • 60% of pts with ARDS in 30days • Can occur as early as 10days • Prevention strategies include-continuous subglottic aspiration of secretions, selective GI tract decontamination ( does not prevent pseudomonas) elevation of head 30 degrees, mouth care, avoiding vent. Circuit changes or clearing the condensate

  27. Nosocomial pneumonia (contd.) • Closed suction is of no benefit • Avoid unnecessary antibiotics • No use of antibiotic or silver impregnated ETT tubes

More Related